111023 MG CME Info

Please Scroll down to Submit

Harnessing the Potential of Individualized Dosing to Improve Outcomes for Patients with Generalized Myasthenia Gravis

Jointly provided by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC, in collaboration with the National Organization for Rare Disorders (NORD), and the Myasthenia Gravis Foundation of America (MGFA)

ACKNOWLEDGEMENT

This activity is supported by an independent educational grant from Argenx US Inc.

DATE OF RELEASE/EXPIRATION

Friday, November 10, 2023 from 12:00-1:00pm ET

TARGET AUDIENCE

The primary target audience for this activity are MDs, NPs, PAs, PharmD/RPh in neurology, neuromuscular, or neuroimmunology disease space.

STATEMENT OF NEED/PROGRAM OVERVIEW

Newer therapies for generalized myasthenia gravis (gMG) now offer an individualized approach to dosing, meaning that treatment dosing regimens can now be tailored to address patients’ fluctuating symptoms of disease, comorbidities, and unique needs and preferences. Individualized treatment and dosing is recommended by the FDA to maximize treatment benefit while minimizing adverse events experienced by patients.

Join expert neurologists Dr. James Howard Jr. and Dr. Pushpa Narayanaswami as they discuss the burden of disease faced by patients with gMG, the rationale for an individualized approach to treatment and dosing in MG to reduce treatment and disease burden and optimize safety, the clinical evidence on available treatment options that incorporate individualized dosing by design, and strategies to engage patients in treatment discussions to account for their unique needs and preferences when determining therapeutic goals

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:

Examine the impact of disease symptom heterogeneity on patients’ perceptions of the burden of disease with gMG.
Discuss the rationale, FDA guidance, and evidence for individualized dosing for patients with neuromuscular diseases, including gMG.
Explain how individualized dosing for gMG can help reduce unnecessary treatment burden and optimize safety, especially for patients with comorbidities.
Incorporate individualized dosing for patients with gMG, considering symptomatology, response to treatment, potential for treatment-free periods, and patient needs and preferences.

JOINT ACCREDITATION STATEMENT

ACPE Logo

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING EDUCATION

PACE designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 60 minutes to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 75% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

FACULTY AND DISCLOSURE OF CONFLICTS OF INTEREST

PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty	Conflicts of Interest
James Howard Jr., MD Professor of Neurology, Medicine & Allied Health	Consultant/Advisory Board/Speaker: AcademicCME, Alexion Pharmaceuticals, Argenx, Biologix Pharma, Medscape CME, Ra Pharmaceuticals (now UCB), F. Hoffmann-LaRoche Ltd., Immunovant, Merck EMB Serono, NMD Pharma, Novartis Pharma, PeerView CME, Regeneron Pharmaceuticals, Sanofi US, Toleranzia AB, Horizon Therapeutics Researcher: Alexion Pharmaceuticals, Argenx, Cartesian Therapeutics, Ra Pharmaceuticals (now UCB)
Pushpa Narayanaswami, MD, FAAN Associate Professor of Neurology Harvard Medical School Vice Chair, Clinical Operations Beth Israel Deaconess Medical Center	Consultant/Advisory Board/Speaker: Alexion Pharmaceuticals, Argenx, Janssen, Dianthus, UCB, GSK Researcher: Momenta/Janssen, Alexion, AstraZeneca, Ra-UCB, Dianthus Other: Data Safety Monitoring Board member-Dianthus

The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The PlatformQ Health Education, LLC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:

For additional information about the accreditation of this activity, please visit https://partnersed.com.

Technical Support:

For any technical issues or issues with your CME Certificate, please contact NueroSeriesLive at 877-394-1306 or at Support@NeuroSeriesLive.com.